SIRPA and neoplasm: Whole body preclinical SPECT/CT imaging using radiolabeled nanobodies targeting SIRPα as performed in the current study provides a proof of concept for in vivo targeting of SIRPα on GBM tumor-infiltrating myeloid cells and confirms the added value and favorable pharmacokinetics of monovalent nanobodies.